|
|
Cyclophosphamide enhances glioma
virotherapy by inhibiting innate immune responses
Giulia Fulci1,2,
Laura Breymann2,
Davide Gianni2, Kazuhiko
Kurozomi1, Sarah
S. Rhee3, Jianhua
Yu5, Balveen
Kaur1, David N.
Louis4, Ralph
Weissleder3, Michael
A. Caligiuri5, and E.
Antonio Chiocca1,2,5,*
1Dardinger Center for
Neuro-Oncology and Neurosciences, Department of Neurological Surgery,
James Cancer Hospital and Solove Research Institute, Ohio State
University Medical Center, Columbus, OH 43210; 2Molecular
Neuro-Oncology Laboratories, Neurosurgery Service, 3Center
for Molecular Imaging Research, and 4Pathology Service,
Massachusetts General Hospital, East Building, 13th Street,
Charlestown, MA 02129; and 5Ohio State University
Comprehensive Cancer Center, Columbus, OH 43210 -- *To whom
correspondence should be addressed at: Dardinger Center for Neuro-Oncology
and Neurosciences, Department of Neurological Surgery, Ohio State
University Medical Center, N-1017 Doan Hall, 410 West 10th Avenue,
Columbus, OH 43210. E-mail: ea.chiocca@osumc.edu. -- Communicated
by Avner Friedman, Ohio State University, Columbus, OH, July 4, 2006
(received for review March 3, 2006). -- Author contributions: G.F. and
E.A.C. designed research; G.F., L.B., D.G., K.K., S.S.R.,
J.Y., and B.K. performed research; D.N.L., R.W., and M.A.C.
contributed new reagents/analytic tools; G.F. analyzed
data; and G.F. and E.A.C. wrote the paper. -- Conflict of interest
statement: No conflicts declared.
|
